Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 2Phase NA 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Radiotherapy 10Early Intervention, Educational 7Standard of Care 6Magnetic Resonance Spectroscopy 6Interviews as Topic 6Educational Status 6Radiotherapy, Conformal 5Practice Guidelines as Topic 5Methods 5Cyclophosphamide 5Vincristine 4Psychiatric Rehabilitation 4Cisplatin 4Brachytherapy 4Biopsy 4Surgical Procedures, Operative 3Specimen Handling 3Radiosurgery 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Etoposide 3Dexamethasone 3Counseling 3Carboplatin 3pegaspargase 2motexafin gadolinium 2etoposide phosphate 2Radiofrequency Ablation 2Radiation 2Preoperative Exercise 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × NETWORK × Fenretinide × Clear all
NCT00017134 2013-06-10

Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk

GOG Foundation

Phase NA Terminated
71 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡